Spots Global Cancer Trial Database for g17dt
Every month we try and update this database with for g17dt cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer | NCT02521649 | Gastric Cancer | G17DT | - | Cancer Advances Inc. | |
| Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer. | NCT02098239 | Jaundice Pancreatic Canc... | G17DT | 18 Years - 90 Years | Cancer Advances Inc. | |
| Effect of G17DT in Patients With Stage II/III Colorectal Cancer | NCT02518373 | Colorectal Canc... | G17DT Omeprazole | 18 Years - | Cancer Advances Inc. | |
| A Study of the Safety and Tolerance of Three Doses of G17DT in Metastatic Colorectal Cancer | NCT02228785 | Colorectal Canc... | G17DT | 18 Years - | Cancer Advances Inc. | |
| An Open Label Study to Evaluate G17DT Compared to Gemcitabine | NCT03200821 | Pancreatic Canc... | G17DT Gemcitabine | 18 Years - | Cancer Advances Inc. | |
| Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients | NCT02518529 | Gastric Cancer | G17DT | 18 Years - | Cancer Advances Inc. | |
| Open-label, Dose-finding Study to Determine Antibody Response to G17DT Treatment in Patients With Gastric Cancer. | NCT02233712 | Gastric Cancer | G17DT | 18 Years - | Cancer Advances Inc. | |
| Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma | NCT00044031 | Pancreatic Canc... | G17DT Immunogen | 18 Years - | Cancer Advances Inc. | |
| Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer | NCT02118077 | Pancreatic Canc... | G17DT | 18 Years - | Cancer Advances Inc. | |
| Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma. | NCT02181465 | Colorectal Canc... | G17DT | 18 Years - 81 Years | Cancer Advances Inc. | |
| Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer. | NCT02098239 | Jaundice Pancreatic Canc... | G17DT | 18 Years - 90 Years | Cancer Advances Inc. | |
| Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer | NCT02521649 | Gastric Cancer | G17DT | - | Cancer Advances Inc. | |
| Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients | NCT02518529 | Gastric Cancer | G17DT | 18 Years - | Cancer Advances Inc. | |
| Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients | NCT02518529 | Gastric Cancer | G17DT | 18 Years - | Cancer Advances Inc. | |
| Two Center Study to Determine Effect of G17DT on Plasma Gastrin Levels in Patients With Colorectal Cancer. | NCT02223078 | Colorectal Canc... | G17DT Placebo Compara... | 18 Years - 90 Years | Cancer Advances Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
